|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We show that both pediatric and adult B-lineage lymphoid malignancies are characterized by a very high incidence of the CD22ΔE12 genetic defect.
|
25567759 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This anti-CD22 VHH with both high affinity and specificity recognizes CD22 antigen well and can be used in diagnosis and treatment of B cell disorders and malignancies.
|
29543347 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies.
|
29662041 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recombinant immunotoxin HA22, composed of an anti- CD22 Fv fragment fused to PE38, a truncated portion of Pseudomonas Exotoxin A (PE), has been developed for targeted treatment of various B-cell malignancies.
|
28039694 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression.
|
30030507 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We subsequently generated mutants containing deletions in this region using HA22, an anti-CD22 Fv-PE38 immunotoxin currently undergoing clinical trials for B-cell malignancies.
|
18988862 |
2009 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since the first approval of gemtuzumab ozogamicin (Mylotarg; Pfizer; CD33 targeted), two additional antibody-drug conjugates (ADC), brentuximab vedotin (Adcetris; Seattle Genetics, Inc.; CD30 targeted) and inotuzumab ozogamicin (Besponsa; Pfizer; CD22 targeted), have been approved for hematologic cancers and 1 ADC, trastuzumab emtansine (Kadcyla; Genentech; HER2 targeted), has been approved to treat breast cancer.
|
30979742 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The manufacturing feasibility of the novel CD22-targeting DAPK immunokinase and its selective antileukemic efficiency encourage intensified studies towards specific clinical application.Mol Cancer Ther; 15(5); 971-84.©2016 AACR.
|
26826117 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-leukemic activity of this RTM against BPL xenograft clones derived from CD22ΔE12(+) leukemia patients provides the preclinical proof-of-concept that correcting the CD22ΔE12 defect with rationally designed CD22 RTMs may provide the foundation for therapeutic innovations that are needed for successful treatment of high-risk and relapsed BPL patients.
|
25567759 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that target antigen modulation is a promising strategy to improve CD22 CAR efficacy and remission durability in patients with leukemia and lymphoma.<i>See related commentary by Guedan and Delgado, p. 5188</i>.
|
31110075 |
2019 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Since latest generation immunotoxins are composed of a toxic domain genetically fused to antibody fragment(s) which confer on the IT target selective specificity, we rescued from the hydridoma 4KB128, a recombinant single-chain variable fragment (scFv) targeting CD22, a marker antigen expressed by B-lineage leukaemias and lymphomas.
|
25889802 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
|
8643111 |
1995 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of this structurally and functionally abnormal CD22 protein is associated with a very aggressive in vivo growth of patients' primary leukemia cells causing disseminated overt leukemia in SCID mice.
|
20841423 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.
|
20628151 |
2010 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with CD34+ leukemia were more likely to have blasts expressing CD22, CD9, and CD13 antigens but were less likely to coexpress CD20.
|
1696310 |
1990 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD22-directed CAR-T cells have shown efficacy against leukemia as well in a recent clinical trial, representing the first alternative CAR target to approach comparable efficacy to CD19 CAR-T cells.
|
30120708 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several other cell surface tumor antigens, such as CD20 and CD22, found in the majority of leukemias and lymphomas are considered potential targets by pharmaceutical companies and research organizations, and trials have been ongoing in this direction.
|
31578576 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data support the testing of RFB4(dsFv)-PE38 in patients with CD22+ leukemias and lymphomas, which is presently under way.
|
10778980 |
2000 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since CD22 is ubiquitously expressed in the B-cell lineage and CD22 endocytosis can be triggered efficiently, antibodies and antibody-based immunotoxins against CD22 are used to target B cells both in B-cell lymphomas and leukemias, as well as in autoimmune diseases.
|
22777817 |
2012 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We have successfully complexed our rationally designed lead CD22-RTM with PVBLG-8 to prepare a non-viral nanoscale formulation of CD22ΔE12-RTM with potent anti-cancer activity against CD22ΔE12(+) B-lineage leukemia and lymphoma cells.
|
26288837 |
2015 |
|
Hairy Cell Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
At progression, viable therapeutic strategies include addition of rituximab to purine analogues, and treatment with the anti-CD22 immunotoxin moxetumomab pasudotox, which has been recently approved by the FDA in HCL patients after at least two prior therapies.
|
31187521 |
2019 |
|
Hairy Cell Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell leukaemia.
|
30357593 |
2018 |
|
Hairy Cell Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD22-targeted recombinant immunotoxins (rIT) are active in hairy cell leukemia or acute lymphoblastic leukemia (ALL), but not in mantle cell lymphoma (MCL) patients.
|
28423727 |
2017 |
|
Hairy Cell Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, the most promising therapeutic strategies for relapsed or refractory HCL include recombinant immunoconjugates targeting CD22 (e.g. moxetumomab pasudotox), BRAF inhibitors such as vemurafenib and B cell receptor signaling kinase inhibitors such as ibrutinib.
|
25563425 |
2015 |
|
Hairy Cell Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-CD22 recombinant immunotoxin Moxetumomab Pasudotox can achieve MRD-negative CR in multiply relapsed HCL without chemotherapy toxicities and was FDA approved in 2018 as Lumoxiti.
|
31068044 |
2019 |